Journal of Renal Nutrition
Volume 21, Issue 3 , Pages 246-256 , May 2011

Association Between Adherence to Folic Acid Supplements and Serum Folate, and Plasma Homocysteine Among Hemodialysis Patients

  • June Leung, PhD, RD

      Affiliations

    • Gerald J. and Dorothy R. Friedman School of Nutrition Science and Policy, Tufts University, Boston, Massachusetts
    • Corresponding Author InformationAddress reprints requests to June Leung, PhD, RD, Frances Stern Nutrition Center, Tufts Medical Center and Gerald J. and Dorothy R. Friedman School of Nutrition Science and Policy, Tufts University, 750 Washington Street-Box 783, Boston, MA 02111.
    • ,
  • Johanna Dwyer, DSc, RD

      Affiliations

    • Gerald J. and Dorothy R. Friedman School of Nutrition Science and Policy, Tufts University, Boston, Massachusetts
    • Department of Medicine and Community Health, Tufts University School of Medicine, Boston, Massachusetts
    • Jean Mayer USDA Human Nutrition Research Center on Aging at Tufts University, Boston, Massachusetts
    • ,
  • Patricia Hibberd, MD, PhD

      Affiliations

    • Department of Public Health and Community Medicine, Tufts University School of Medicine, Boston, Massachusetts
    • Department of Medicine, Tufts University School of Medicine, Boston, Massachusetts
    • Department of Pediatrics, Tufts University School of Medicine, Boston, Massachusetts
    • ,
  • Paul Jacques, ScD

      Affiliations

    • Gerald J. and Dorothy R. Friedman School of Nutrition Science and Policy, Tufts University, Boston, Massachusetts
    • Jean Mayer USDA Human Nutrition Research Center on Aging at Tufts University, Boston, Massachusetts
    • ,
  • William Rand, PhD

      Affiliations

    • Department of Public Health and Community Medicine, Tufts University School of Medicine, Boston, Massachusetts
    • ,
  • Michael V. Rocco, MD

      Affiliations

    • Internal Medicine-Nephrology, Wake Forest University School of Medicine, Winston-Salem, North Carolina
    • ,
  • HEMO Study Group

References 

  1. Makoff R. Vitamin replacement therapy in renal failure patients. Miner Electrolyte Metab. 1999;25:349–351
  2. Makoff R, Gonick H. Renal failure and the concomitant derangement of micronutrient metabolism. Nutr Clin Pract. 1999;14:238–246
  3. Descombes E, Hanck AB, Fellay G. Water soluble vitamins in chronic hemodialysis patients and need for supplementation. Kidney Int. 1993;43:1319–1328
  4. Stein G, Sperschneider H, Koppe S. Vitamin levels in chronic renal failure and need for supplementation. Blood Purif. 1985;3:52–62
  5. Levey AS, Beto JA, Coronado BE, et al. Controlling the epidemic of cardiovascular disease in chronic renal disease: what do we know? What do we need to learn? Where do we go from here?. Am J Kidney Dis. 1998;32:853–906
  6. National Kidney Foundation (NKF) Kidney Disease Outcome Quality Initiative (K/DOQI) Advisory Board: K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis. 2002;39(Suppl 2):S1–S246
  7. Manns BJ, Burgess ED, Hyndman ME, et al. Hyperhomocysteinemia and the prevalence of atherosclerotic vascular disease in patients with end stage renal disease. Am J Kidney Dis. 1998;32:669–677
  8. Selhub J, Jacques P, Bostom A, et al. Relationship between plasma homocysteine, vitamin status and extracranial carotid-artery stenosis in the Framingham Study population. J Nutr. 1996;126(Suppl 4):S1258–S1265
  9. Clarke R, Daly L, Robinson K, et al. Hyperhomocysteinemia: an independent risk factor for vascular disease. N Engl J Med. 1991;324:1149–1155
  10. Boushey CJ, Beresford SA, Omenn GS, et al. Quantitative assessment of plasma homocysteine as a risk factor for vascular disease. JAMA. 1995;274:1049–1057
  11. Chauveau P, Chadefaux B, Coudé M, et al. Hyperhomocysteinemia, a risk factor for atherosclerosis in chronic uremic patients. Kidney Int. 1993;41(Suppl 1):S72–S77
  12. Robinson K, Gupta A, Dennis V, et al. Hyperhomocysteinemia confers an independent increased risk of atherosclerosis in end-stage renal disease and is closely linked to plasma folate and pyridoxine concentrations. Circulation. 1996;94:2743–2748
  13. Eikelboom JW, Lonn E, Genest J, et al. Homocyst(e)ine and cardiovascular disease: a critical review of the epidemiologic evidence. Ann Intern Med. 1999;131:363–375
  14. McCully KS. Homocysteine and vascular disease. Nat Med. 1996;2:386–389
  15. Kang SS, Wong PW, Malinow MR. Hyperhomocyst(e)inemia as a risk factor for occlusive vascular disease. Annu Rev Nutr. 1999;2:279–298
  16. De Vecchi AF, Bamonti-Catena F, Finazzi S, et al. Homocysteine, vitamin B12, and serum and erythrocyte folate in peritoneal dialysis and hemodialysis patients. Perit Dial Int. 2000;20:169–173
  17. Bostom AG, Shemin D, Verhoef P, et al. Elevated fasting total plasma homocysteine levels and cardiovascular disease outcomes in maintenance dialysis patients: a prospective study. Arterioscler Thromb Vasc Biol. 1997;17:2554–2558
  18. Friedman AN, Bostom AG, Selhub J, et al. The kidney and homocysteine metabolism. J Am Soc Nephrol. 2001;12:2181–2189
  19. Moustapha A, Gupta A, Robinson K, et al. Prevalence and determinants of hyperhomocysteinemia in hemodialysis and peritoneal dialysis. Kidney Int. 1999;55:1470–1475
  20. Dierkes J, Domrose U, Bosselmann KP, et al. Homocysteine lowering effect of different multi-vitamin preparations in patients with end-stage renal disease. J Ren Nutr. 2001;11:67–72
  21. Bostom AG, Shemin D, Bagley P, et al. Controlled comparison of L-5-methyltetrahydrofolate versus folic acid for the treatment of hyperhomocysteinemia in hemodialysis patients. Circulation. 2000;101:2829–2832
  22. Wrone EM, Hornberger JM, Zehnder JL, et al. Randomized trial of folic acid for prevention of cardiovascular events in end-stage renal disease. J Am Soc Nephrol. 2004;15:420–426
  23. Righetti M, Serbelloni P, Milani S, et al. Homocysteine-lowering vitamin B treatment decreases cardiovascular events in hemodialysis patients. Blood Purif. 2006;24:379–386
  24. Zoungas S, McGrath BP, Branley P, et al. Cardiovascular morbidity and mortality in the Atherosclerosis and Folic Acid Supplementation Trial (ASFAST) in chronic renal failure: a multicenter, randomized, controlled trial. J Am Coll Cardiol. 2006;47:1108–1116
  25. Jamison RL, Hartigan P, Kaufman JS, et al. Effect of homocysteine lowering on mortality and vascular disease in advanced chronic kidney disease and end stage renal disease. JAMA. 2007;298:1163–1170
  26. Karamanidou C, Clatworthy J, Weinman J, et al. A systematic review of the prevalence and determinants of nonadherence to phosphate binding medication in patients with end-stage renal disease. BMC Nephrol. 2008;9:2;Available at http://www.biomedcentral.com/1471-2369/9/2
  27. Schmid H, Hartmann B, Schiffl H. Adherence to prescribed oral medication in adult patients undergoing chronic hemodialysis: a critical review of the literature. Eur J Med Res. 2009;14:185–190
  28. Descombes E, Boulat O, Perriard F, et al. Water-soluble vitamin levels in patients undergoing high-flux hemodialysis and receiving long-term oral postdialysis vitamin supplementation. Artif Organs. 2000;24:773–778
  29. Mitch WE, Maroni BJ. Factors causing malnutrition in patients with chronic uremia. Am J Kidney Dis. 1999;33:176–179
  30. Leung J, Dwyer J. Renal DETERMINE nutrition screening tools for the identification and treatment of malnutrition. J Ren Nutr. 1998;8:95–103
  31. Eknoyan G, Beck GJ, Cheung AK, et al. Effect of dialysis dose and membrane flux in maintenance hemodialysis. N Engl J Med. 2002;347:2010–2019
  32. United States Food and Drug Administration: Food standards: amendment of standards of identity for enriched grain products to require addition of folic acid. Fed Regist. 1996;61:8781–8797
  33. United States Department of Agriculture, Agriculture Research Service: USDA National Nutrient Database for Standard Reference, Release 21. 2008. Available at: http://www.ars.usda.gov/ba/bhnrc/ndl. Accessed November 2008 [retrieved from Nutrient Data Laboratory Home Page]
  34. Araki A, Sako Y. Determination of free and total homocysteine in human plasma by high-performance liquid chromatography with fluorescence detection. J Chromatogr. 1987;422:43–53
  35. Shin-Buehring Y, Rasshofer R, Endres W. A new enzymatic method for pyridoxal-5'-phosphate determination. J Inherit Metab Dis. 1981;4:123–124
  36. Miskulin DC, Athienites NV, Yan G, et al. Comorbidity assessment using the Index of Coexistent Diseases in a multicenter clinical trial. Kidney Int. 2001;60:1498–1510
  37. Hirth RA, Greer SL, Albert JM, et al. Out-of-pocket spending and medication adherence among dialysis patients in twelve countries. Health Aff. 2008;27:89–102
  38. Holley JL, DeVore CC. Why all prescribed medications are not taken: results from a survey of chronic dialysis patients. Adv Perit Dial. 2006;22:162–166
  39. Jacques PF, Selhub J, Bostom AG, et al. The effect of folic acid fortification on plasma folate and total homocysteine concentrations. N Engl J Med. 2000;340:1449–1454
  40. Galloway M, Rushworth L. Red cell or serum folate? Results from the National Pathology Alliance benchmarking review. J Clin Pathol. 2003;56:924–926
  41. Satia-Abouta J, Patterson RE, King IB, et al. Reliability and validity of self-report of vitamin and mineral supplement use in the vitamins and lifestyle study. Am J Epidemiol. 2003;157:944–954
  42. Block G, Sinha R, Gridley G. Collection of dietary-supplement data and implications for analysis. Am J Clin Nutr. 1994;59(Suppl 1):S232–S239
  43. Patterson RE, Kristal AR, Levy L, et al. Validity of methods used to assess vitamin and mineral supplement use. Am J Epidemiol. 1998;148:643–649
  44. Pancharuniti N, Lewis CA, Sauberlich HE, et al. Plasma homocyst(e)ine, folate, and vitamin B-12 concentrations and risk for early-onset coronary artery disease. Am J Clin Nutr. 1994;59:940–948
  45. Giles WH, Kittner SJ, Anda RF, et al. Serum folate and risk for ischemic stroke. First National Health and Nutrition Examination Survey epidemiologic follow-up study. Stroke. 1995;26:1166–1170
  46. Morrison HI, Schaubel D, Desmeules M, et al. Serum folate and risk of fatal coronary heart disease. JAMA. 1996;275:1893–1896
  47. Robinson K, Arheart K, Refsum H, et al. European COMAC Group Low circulating folate and vitamin B6 concentrations: risk factors for stroke, peripheral vascular disease, and coronary artery disease. Circulation. 1998;97:437–443
  48. Graham IM, Daly LE, Refsum HM, et al. Plasma homocysteine as a risk factor for vascular disease. The European Concerted Action Project. JAMA. 1997;277:1775–1781
  49. Rimm EB, Willett WC, Hu FB, et al. Folate and vitamin B6 from diet and supplements in relation to risk of coronary heart disease among women. JAMA. 1998;279:359–364
  50. Toole JF, Malinow MR, Chambless LE, et al. Lowering homocysteine in patients with ischemic stroke to prevent recurrent stroke, myocardial infarction, and death: the Vitamin Intervention for Stroke Prevention (VISP) randomized controlled trial. JAMA. 2004;291:565–575
  51. Schnyder G, Roffi M, Flammer Y, et al. Effect of homocysteine-lowering therapy with folic acid, vitamin B12, and vitamin B6 on clinical outcome after percutaneous coronary intervention: the Swiss Heart study: a randomized controlled trial. JAMA. 2002;288:973–979
  52. Bonaa KH, Njolstad I, Ueland PM, et al. NORVIT Trial Investigators. Homocysteine lowering and cardiovascular events after acute myocardial infarction. N Engl J Med. 2006;354:1578–1588
  53. Lonn E, Yusuf S, Arnold MJ, et al. Heart Outcomes Prevention Evaluation (HOPE) 2 Investigators. Homocysteine lowering with folic acid and B vitamins in vascular disease. N Engl J Med. 2006;354:1567–1577
  54. Albert CM, Cook NR, Gaziano JM, et al. Effect of folic acid and B vitamins on risk of cardiovascular events and total mortality among women at high risk for cardiovascular disease. JAMA. 2008;299:2027–2036
  55. Ebbing M, Bleie O, Ueland PM, et al. Mortality and cardiovascular events in patients treated with homocysteine-lowering B vitamins after coronary angiography. JAMA. 2008;300:795–804
  56. Baker F, Picton D, Blackwood S. Blinded comparison of folic acid and placebo in patients with ischemic heart disease: an outcome trial. Circulation. 2002;19:A3642
  57. Leung J, Dwyer J, Hibberd P, et al: Folic acid supplementation and cardiac and stroke mortality among hemodialysis patients. J Ren Nutr (in press)
  58. MacMahon M, Kirkpatrick C, Cummings CE, et al. A pilot study with simvastatin and folic acid/vitamin B12 in preparation for the Study of the Effectiveness of Additional Reductions in Cholesterol and Homocysteine (SEARCH). Nutr Metab Cardiovasc Dis. 2000;10:195–203
  59. VITATOPS Trial Study Group. The VITATOPS (Vitamins to Prevent Stroke) Trial: rationale and design of an international, large, simple, randomised trial of homocysteine-lowering multivitamin therapy in patients with recent transient ischaemic attack or stroke. Cerebrovasc Dis. 2002;13:120–126
  60. Galan P, de Bree A, Mennen L, et al. Background and rationale of the SU.FOL.OM3 study: double-blind randomized placebo-controlled secondary prevention trial to test the impact of supplementation with folate, vitamin B6 and B12 and/or omega-3 fatty acids on the prevention of recurrent ischemic events in subjects with atherosclerosis in the coronary or cerebral arteries. J Nutr Health Aging. 2003;7:428–435
  61. Bostom AG, Carpenter MA, Kusek JW, et al. Rationale and design of the Folic Acid for Vascular Outcome Reduction in Transplantation (FAVORIT) trial. Am Heart J. 2006;152:448.e1–448.e7
  62. B Vitamin Treatment Trialists' Collaboration. Homocysteine-lowering trials for prevention of cardiovascular events: a review of the design and power of the large randomized trials. Am Heart J. 2006;151:282–287
  63. National Academy of Sciences, Institute of Medicine, Food and Nutrition Board: Dietary Reference Intakes for Thiamin, Riboflavin, Niacin, Vitamin B6, Folate, Vitamin B12, Pantothenic Acid, Biotin, and Choline. Washington, DC: National Academy Press; 1998;

 Supported by the National Institute of Diabetes, Digestive and Kidney Diseases (NIDDK) of the National Institutes of Health and the National Kidney Foundation Council on Renal Nutrition Research Grant. This work was also supported in part with resources from the US Department of Agriculture (USDA), Agricultural Research Service, under agreement 58-2950-7-707. Any opinions, findings, conclusions or recommendations expressed here are those of the authors and do not necessarily reflect the view of the USDA.

PII: S1051-2276(10)00108-1

doi: 10.1053/j.jrn.2010.04.005

Journal of Renal Nutrition
Volume 21, Issue 3 , Pages 246-256 , May 2011

Article Tools